JP2009530408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530408A5 JP2009530408A5 JP2009501606A JP2009501606A JP2009530408A5 JP 2009530408 A5 JP2009530408 A5 JP 2009530408A5 JP 2009501606 A JP2009501606 A JP 2009501606A JP 2009501606 A JP2009501606 A JP 2009501606A JP 2009530408 A5 JP2009530408 A5 JP 2009530408A5
- Authority
- JP
- Japan
- Prior art keywords
- pge2
- acid
- hsc
- dimethyl
- deoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 30
- -1 Bapta-AM Chemical compound 0.000 claims 17
- 229960002986 dinoprostone Drugs 0.000 claims 15
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 15
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 claims 10
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 10
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims 8
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims 8
- 102000008866 Prostaglandin E receptors Human genes 0.000 claims 6
- 108010088540 Prostaglandin E receptors Proteins 0.000 claims 6
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 claims 5
- UNSRRHDPHVZAHH-YOILPLPUSA-N (5Z,8Z,11Z)-icosatrienoic acid Chemical compound CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(O)=O UNSRRHDPHVZAHH-YOILPLPUSA-N 0.000 claims 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 5
- XTNOEYFQXCQKLC-UHFFFAOYSA-N 18-(oxiren-2-yl)octadeca-15,17-dienoic acid Chemical compound C1=C(C=CC=CCCCCCCCCCCCCCC(=O)O)O1 XTNOEYFQXCQKLC-UHFFFAOYSA-N 0.000 claims 5
- UNSRRHDPHVZAHH-UHFFFAOYSA-N 6beta,11alpha-Dihydroxy-3alpha,5alpha-cyclopregnan-20-on Natural products CCCCCCCCC=CCC=CCC=CCCCC(O)=O UNSRRHDPHVZAHH-UHFFFAOYSA-N 0.000 claims 5
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 claims 5
- 230000035755 proliferation Effects 0.000 claims 5
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 claims 5
- 239000000018 receptor agonist Substances 0.000 claims 5
- 229940044601 receptor agonist Drugs 0.000 claims 5
- MWYHLEQJTQJHSS-UHFFFAOYSA-N tomelukast Chemical compound C1=CC(C(C)=O)=C(O)C(CCC)=C1OCCCCC1=NNN=N1 MWYHLEQJTQJHSS-UHFFFAOYSA-N 0.000 claims 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 4
- LLVVDFDWPQHXBA-QEJIITRLSA-N 11-Deoxy-16,16-dimethyl-PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1CCC(=O)[C@@H]1C\C=C/CCCC(O)=O LLVVDFDWPQHXBA-QEJIITRLSA-N 0.000 claims 4
- XSGQFHNPNWBVPT-DSFPJDRCSA-N 15-Methyl-15S-PGE2 Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XSGQFHNPNWBVPT-DSFPJDRCSA-N 0.000 claims 4
- XSGQFHNPNWBVPT-VFXMVCAWSA-N 15-methyl-15R-PGE2 Chemical compound CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XSGQFHNPNWBVPT-VFXMVCAWSA-N 0.000 claims 4
- WTJYDBMHYPQFNJ-ZUVVJKHESA-N 19R-Hydroxy-PGE2 Chemical compound C[C@@H](O)CCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O WTJYDBMHYPQFNJ-ZUVVJKHESA-N 0.000 claims 4
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 claims 4
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 4
- WMLGLMGSFIXSGO-KTXJXPLISA-N 9-Deoxy-9-methylene-16,16-dimethyl -PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(O)=O WMLGLMGSFIXSGO-KTXJXPLISA-N 0.000 claims 4
- VKEJXDXJUFQESA-DLMPNJEASA-N 9-Deoxy-9-methylene-PGE2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(O)=O VKEJXDXJUFQESA-DLMPNJEASA-N 0.000 claims 4
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 claims 4
- 101800004538 Bradykinin Proteins 0.000 claims 4
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims 4
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims 4
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 4
- 102100035792 Kininogen-1 Human genes 0.000 claims 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 4
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 4
- 125000002575 PGE2 group Chemical group 0.000 claims 4
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 claims 4
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 claims 4
- 229960002873 benfotiamine Drugs 0.000 claims 4
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 claims 4
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 4
- 229950008654 butaprost Drugs 0.000 claims 4
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 claims 4
- 229960001761 chlorpropamide Drugs 0.000 claims 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims 4
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 claims 4
- 229960004042 diazoxide Drugs 0.000 claims 4
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims 4
- 229960004979 fampridine Drugs 0.000 claims 4
- 229960002602 fendiline Drugs 0.000 claims 4
- 229950004346 gaboxadol Drugs 0.000 claims 4
- ICLWTJIMXVISSR-UHFFFAOYSA-N gallamine Chemical compound CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC ICLWTJIMXVISSR-UHFFFAOYSA-N 0.000 claims 4
- 229960003054 gallamine Drugs 0.000 claims 4
- 229960002474 hydralazine Drugs 0.000 claims 4
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 4
- 229960004801 imipramine Drugs 0.000 claims 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 claims 4
- 229940124280 l-arginine Drugs 0.000 claims 4
- XRISENIKJUKIHD-LHQZMKCDSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,4r)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoate Chemical compound CCCC1([C@H](O)C\C=C\[C@@H]2[C@H](C(=O)C[C@H]2O)CCCCCCC(=O)OC)CCC1 XRISENIKJUKIHD-LHQZMKCDSA-N 0.000 claims 4
- 229960001783 nicardipine Drugs 0.000 claims 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 4
- 229960001597 nifedipine Drugs 0.000 claims 4
- 229960005152 pentetrazol Drugs 0.000 claims 4
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims 4
- 229960003634 pimozide Drugs 0.000 claims 4
- 229960002508 pindolol Drugs 0.000 claims 4
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 4
- WGCXTGBZBFBQPP-UHFFFAOYSA-N prostaglandin E2 methyl ester Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(=O)OC WGCXTGBZBFBQPP-UHFFFAOYSA-N 0.000 claims 4
- 229930182884 serinolamide Natural products 0.000 claims 4
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 claims 4
- 229940083618 sodium nitroprusside Drugs 0.000 claims 4
- ODJLBQGVINUMMR-HZXDTFASSA-N strophanthidin Chemical compound C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@@]5(O)CC4)C=O)CC[C@@]32C)=CC(=O)OC1 ODJLBQGVINUMMR-HZXDTFASSA-N 0.000 claims 4
- 229910000166 zirconium phosphate Inorganic materials 0.000 claims 4
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims 3
- 229930188389 Lanatoside Natural products 0.000 claims 3
- ODJLBQGVINUMMR-UHFFFAOYSA-N Strophanthidin Natural products CC12CCC(C3(CCC(O)CC3(O)CC3)C=O)C3C1(O)CCC2C1=CC(=O)OC1 ODJLBQGVINUMMR-UHFFFAOYSA-N 0.000 claims 3
- YFGQJKBUXPKSAW-ZUDKKNPISA-N [(2r,3r,4s)-6-[(2r,3s,4s)-4-hydroxy-6-[(2r,3s,4s)-4-hydroxy-6-[[(3s,9s,10s,13r,17r)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-y Chemical compound O([C@H]1[C@@H](OC(C)=O)CC(O[C@@H]1C)O[C@H]1[C@@H](O)CC(O[C@@H]1C)O[C@H]1[C@@H](O)CC(O[C@@H]1C)O[C@@H]1CC2[C@]([C@@H]3C(C4(CC[C@@H]([C@@]4(C)CC3)C=3COC(=O)C=3)O)CC2)(C)CC1)C1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O YFGQJKBUXPKSAW-ZUDKKNPISA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 229960002274 atenolol Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001737 promoting effect Effects 0.000 claims 3
- DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 claims 3
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims 3
- 239000004308 thiabendazole Substances 0.000 claims 3
- 229960004546 thiabendazole Drugs 0.000 claims 3
- 235000010296 thiabendazole Nutrition 0.000 claims 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 2
- IOFUFYLETVNNRF-OSAZKUMMSA-N (1R,2R,5S)-AH23848 Chemical compound N1([C@H]2C(=O)C[C@@H]([C@@H]2CC\C=C/CCC(=O)O)OCC=2C=CC(=CC=2)C=2C=CC=CC=2)CCOCC1 IOFUFYLETVNNRF-OSAZKUMMSA-N 0.000 claims 2
- JEJQBJWFMRKQJY-UHFFFAOYSA-N 12-methoxydodec-2-enoic acid Chemical compound COCCCCCCCCCC=CC(O)=O JEJQBJWFMRKQJY-UHFFFAOYSA-N 0.000 claims 2
- WXBXVVIUZANZAU-UHFFFAOYSA-N 2E-decenoic acid Natural products CCCCCCCC=CC(O)=O WXBXVVIUZANZAU-UHFFFAOYSA-N 0.000 claims 2
- AQFFXPQJLZFABJ-UHFFFAOYSA-N 9-oxo-6-propan-2-yloxy-2-xanthenecarboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(=O)C3=CC=C(OC(C)C)C=C3OC2=C1 AQFFXPQJLZFABJ-UHFFFAOYSA-N 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
- PQUGCKBLVKJMNT-UHFFFAOYSA-N SC560 Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(F)(F)F)=N1 PQUGCKBLVKJMNT-UHFFFAOYSA-N 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 claims 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 claims 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 claims 2
- 229960001395 fenbufen Drugs 0.000 claims 2
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims 2
- 210000004700 fetal blood Anatomy 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- QTDZOWFRBNTPQR-UHFFFAOYSA-N guvacine Chemical compound OC(=O)C1=CCCNC1 QTDZOWFRBNTPQR-UHFFFAOYSA-N 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 2
- 229960004773 losartan Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 2
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 claims 2
- 229960000894 sulindac Drugs 0.000 claims 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 2
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical compound CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims 1
- ZKZXNDJNWUTGDK-NSCUHMNNSA-N (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide Chemical compound C1=CC(Br)=CC=C1\C=C\CNCCNS(=O)(=O)C1=CC=CC2=CN=CC=C12 ZKZXNDJNWUTGDK-NSCUHMNNSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- QAOBBBBDJSWHMU-JQAHBYNNSA-N (e)-7-[3-hydroxy-2-[(e)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid Chemical group CCCCC(C)(C)C(O)\C=C\C1C(O)CC(=O)C1C\C=C\CCCC(O)=O QAOBBBBDJSWHMU-JQAHBYNNSA-N 0.000 claims 1
- LJOQGZACKSYWCH-LHHVKLHASA-N (s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol Chemical compound C1=C(OC)C=C2C([C@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-LHHVKLHASA-N 0.000 claims 1
- SNTQPLDRUZOSDP-UHFFFAOYSA-N 2,2-diphenylpentanoic acid 2-(diethylamino)ethyl ester Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(CC)CC)(CCC)C1=CC=CC=C1 SNTQPLDRUZOSDP-UHFFFAOYSA-N 0.000 claims 1
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 claims 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims 1
- WBLZUCOIBUDNBV-UHFFFAOYSA-N 3-nitropropanoic acid Chemical compound OC(=O)CC[N+]([O-])=O WBLZUCOIBUDNBV-UHFFFAOYSA-N 0.000 claims 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 claims 1
- HJDRXEQUFWLOGJ-AJNGGQMLSA-N Ac-Ser-Asp-Lys-Pro-OH Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(O)=O HJDRXEQUFWLOGJ-AJNGGQMLSA-N 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 claims 1
- LJOQGZACKSYWCH-AFHBHXEDSA-N Hydroquinidine Natural products C1=C(OC)C=C2C([C@@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-AFHBHXEDSA-N 0.000 claims 1
- ZHEHVZXPFVXKEY-RUAOOFDTSA-N KT 5720 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@@H]1C[C@](C(=O)OCCCCCC)(O)[C@@]4(C)O1 ZHEHVZXPFVXKEY-RUAOOFDTSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 claims 1
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 claims 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 claims 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 claims 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims 1
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims 1
- 229960004176 aclarubicin Drugs 0.000 claims 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims 1
- SLRCCWJSBJZJBV-UHFFFAOYSA-N alpha-isosparteine Natural products C1N2CCCCC2C2CN3CCCCC3C1C2 SLRCCWJSBJZJBV-UHFFFAOYSA-N 0.000 claims 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims 1
- 229960005174 ambroxol Drugs 0.000 claims 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 claims 1
- 229960002469 antazoline Drugs 0.000 claims 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims 1
- 235000013734 beta-carotene Nutrition 0.000 claims 1
- 239000011648 beta-carotene Substances 0.000 claims 1
- 229960002747 betacarotene Drugs 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229940043370 chrysin Drugs 0.000 claims 1
- 235000015838 chrysin Nutrition 0.000 claims 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 1
- 229960001214 clofibrate Drugs 0.000 claims 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims 1
- 229960004704 dihydroergotamine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- 229960002179 ephedrine Drugs 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 claims 1
- 229950006566 etanidazole Drugs 0.000 claims 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 claims 1
- 229960004511 fludroxycortide Drugs 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 229960003883 furosemide Drugs 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 108010031357 goralatide Proteins 0.000 claims 1
- 229960002350 guaiazulen Drugs 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 229960000811 hydroquinidine Drugs 0.000 claims 1
- QQUXFYAWXPMDOE-UHFFFAOYSA-N kenpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 claims 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 claims 1
- 229960000907 methylthioninium chloride Drugs 0.000 claims 1
- 229940053934 norethindrone Drugs 0.000 claims 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 1
- 229960001639 penicillamine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960001181 phenazopyridine Drugs 0.000 claims 1
- 229960003418 phenoxybenzamine Drugs 0.000 claims 1
- 229960003562 phentermine Drugs 0.000 claims 1
- 229950004490 proadifen Drugs 0.000 claims 1
- 229960003712 propranolol Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- SLRCCWJSBJZJBV-AJNGGQMLSA-N sparteine Chemical compound C1N2CCCC[C@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 SLRCCWJSBJZJBV-AJNGGQMLSA-N 0.000 claims 1
- 229960001945 sparteine Drugs 0.000 claims 1
- 229960003400 sulprostone Drugs 0.000 claims 1
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 claims 1
- 229960002178 thiamazole Drugs 0.000 claims 1
- 229940045136 urea Drugs 0.000 claims 1
- 229940102566 valproate Drugs 0.000 claims 1
- YSSBJODGIYRAMI-UHFFFAOYSA-N vesamicol Chemical compound OC1CCCCC1N1CCC(C=2C=CC=CC=2)CC1 YSSBJODGIYRAMI-UHFFFAOYSA-N 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78596806P | 2006-03-24 | 2006-03-24 | |
| US60/785,968 | 2006-03-24 | ||
| PCT/US2007/007419 WO2007112084A2 (en) | 2006-03-24 | 2007-03-26 | Method to modulate hematopoietic stem cell growth |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013046473A Division JP6041711B2 (ja) | 2006-03-24 | 2013-03-08 | 造血性幹細胞の増殖を調節する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009530408A JP2009530408A (ja) | 2009-08-27 |
| JP2009530408A5 true JP2009530408A5 (enExample) | 2010-04-15 |
| JP5247675B2 JP5247675B2 (ja) | 2013-07-24 |
Family
ID=38526581
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009501606A Active JP5247675B2 (ja) | 2006-03-24 | 2007-03-26 | 造血性幹細胞の増殖を調節する方法 |
| JP2013046473A Expired - Fee Related JP6041711B2 (ja) | 2006-03-24 | 2013-03-08 | 造血性幹細胞の増殖を調節する方法 |
| JP2015147317A Active JP6208719B2 (ja) | 2006-03-24 | 2015-07-27 | 造血性幹細胞の増殖を調節する方法 |
| JP2016175313A Expired - Fee Related JP6530732B2 (ja) | 2006-03-24 | 2016-09-08 | 造血性幹細胞の増殖を調節する方法 |
| JP2019027038A Expired - Fee Related JP6797222B2 (ja) | 2006-03-24 | 2019-02-19 | 造血性幹細胞の増殖を調節する方法 |
| JP2019171346A Withdrawn JP2019214620A (ja) | 2006-03-24 | 2019-09-20 | 造血性幹細胞の増殖を調節する方法 |
| JP2021170835A Pending JP2022025091A (ja) | 2006-03-24 | 2021-10-19 | 造血性幹細胞の増殖を調節する方法 |
| JP2023098876A Pending JP2023112027A (ja) | 2006-03-24 | 2023-06-16 | 造血性幹細胞の増殖を調節する方法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013046473A Expired - Fee Related JP6041711B2 (ja) | 2006-03-24 | 2013-03-08 | 造血性幹細胞の増殖を調節する方法 |
| JP2015147317A Active JP6208719B2 (ja) | 2006-03-24 | 2015-07-27 | 造血性幹細胞の増殖を調節する方法 |
| JP2016175313A Expired - Fee Related JP6530732B2 (ja) | 2006-03-24 | 2016-09-08 | 造血性幹細胞の増殖を調節する方法 |
| JP2019027038A Expired - Fee Related JP6797222B2 (ja) | 2006-03-24 | 2019-02-19 | 造血性幹細胞の増殖を調節する方法 |
| JP2019171346A Withdrawn JP2019214620A (ja) | 2006-03-24 | 2019-09-20 | 造血性幹細胞の増殖を調節する方法 |
| JP2021170835A Pending JP2022025091A (ja) | 2006-03-24 | 2021-10-19 | 造血性幹細胞の増殖を調節する方法 |
| JP2023098876A Pending JP2023112027A (ja) | 2006-03-24 | 2023-06-16 | 造血性幹細胞の増殖を調節する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US8168428B2 (enExample) |
| EP (3) | EP2423303A1 (enExample) |
| JP (8) | JP5247675B2 (enExample) |
| CN (2) | CN102626517B (enExample) |
| AU (1) | AU2007230902B2 (enExample) |
| CA (1) | CA2647201C (enExample) |
| MX (3) | MX373998B (enExample) |
| RU (2) | RU2425876C2 (enExample) |
| WO (1) | WO2007112084A2 (enExample) |
| ZA (2) | ZA200808123B (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX373998B (es) | 2006-03-24 | 2020-07-22 | Childrens Medical Center | Uso de un modulador de células madre hematopoyeticas (hsc) para promover el crecimiento de hsc. |
| JP5426389B2 (ja) | 2006-10-20 | 2014-02-26 | チルドレンズ メディカル センター コーポレーション | 組織の再生を亢進するための方法 |
| WO2008073748A1 (en) * | 2006-12-08 | 2008-06-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| US8263403B2 (en) * | 2007-04-23 | 2012-09-11 | Stowers Institute For Medical Research | Methods and compositions for stem cell self-renewal |
| US8871752B2 (en) * | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
| ITUD20080058A1 (it) | 2008-03-18 | 2009-09-19 | Thankstem S R L | Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali |
| US20110206781A1 (en) * | 2008-05-28 | 2011-08-25 | Zon Leonard I | Method to modulate hematopoietic stem cell growth |
| CN107523587A (zh) | 2008-11-06 | 2017-12-29 | 印第安纳大学研究与技术公司 | 增强造血干细胞植入过程的材料和方法 |
| WO2010091052A2 (en) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| WO2010096264A2 (en) | 2009-02-03 | 2010-08-26 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| US20120202288A1 (en) * | 2009-03-19 | 2012-08-09 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| US20120195862A1 (en) * | 2009-04-17 | 2012-08-02 | Children's Medical Center Corporation | Biomechanical induction of hematopoiesis |
| EP2251010A1 (en) | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Use of thiabendazole and derivatives thereof for the therapy of neurological conditions |
| JP6037836B2 (ja) * | 2009-11-15 | 2016-12-07 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | 特異的プロスタグランジンｅ２受容体の特定を含む幹細胞の送達及び生着を高めるための方法 |
| US20130129686A1 (en) * | 2009-11-19 | 2013-05-23 | Regents Of The University | Reducing Inflammation Using Cell Therapy |
| WO2011143125A2 (en) * | 2010-05-10 | 2011-11-17 | Fate Therapeutics, Inc. | Biovessels |
| CN112501118A (zh) * | 2010-08-12 | 2021-03-16 | 菲特治疗公司 | 改进的造血干细胞和祖细胞疗法 |
| DK2663313T3 (en) * | 2011-01-13 | 2018-11-26 | Scipharm S A R L | PROCEDURE FOR IMPROVING ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS |
| EP2701694A4 (en) * | 2011-04-28 | 2014-10-08 | Univ Duke | METHOD FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| CN108220246B (zh) | 2011-09-30 | 2022-07-12 | 蓝鸟生物公司 | 用于改善病毒转导的化合物 |
| ES2682255T3 (es) | 2011-12-02 | 2018-09-19 | Fate Therapeutics, Inc. | Métodos mejorados de tratamiento de isquemia |
| PT2785834T (pt) | 2011-12-02 | 2020-11-13 | Fate Therapeutics Inc | Composição de células estaminais melhorada |
| WO2013086029A1 (en) | 2011-12-05 | 2013-06-13 | Primorigen Biosciences Inc. | Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof |
| WO2014015318A1 (en) * | 2012-07-19 | 2014-01-23 | Bluebird Bio, Inc. | Soluble compounds for improved gene therapy methods |
| WO2014081760A1 (en) | 2012-11-20 | 2014-05-30 | Duke University | Methods of treating hemoglobinopathies |
| US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| EP2968416A4 (en) | 2013-03-15 | 2016-08-17 | Fate Therapeutics Inc | CELL POTENTIAL TEST FOR THERAPEUTIC POTENTIAL |
| US9428748B2 (en) * | 2013-06-17 | 2016-08-30 | Hong Gao | Method of expanding hematopoietic stem cells |
| JP2015205835A (ja) * | 2014-04-21 | 2015-11-19 | 国立大学法人福井大学 | 中性子線障害防護剤 |
| EP3134096A4 (en) * | 2014-04-23 | 2018-01-10 | Texas Heart Institute | Methods of enhancing stem cell engraftment |
| US9816074B2 (en) | 2014-07-25 | 2017-11-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
| US10435677B2 (en) | 2014-09-16 | 2019-10-08 | Sangamo Therapeutics, Inc. | Genetically modified human cell with a corrected mutant sickle cell mutation |
| JP6800859B2 (ja) | 2015-01-26 | 2020-12-16 | フェイト セラピューティクス，インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
| EP3313420B1 (en) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| AU2016296741A1 (en) | 2015-07-21 | 2018-02-22 | The Children's Medical Center Corporation | PD-L1 expressing hematopoietic stem cells and uses |
| CN105296427A (zh) * | 2015-10-23 | 2016-02-03 | 深圳爱生再生医学科技有限公司 | 造血干细胞的体外扩增培养方法 |
| WO2017073692A1 (ja) * | 2015-10-30 | 2017-05-04 | 国立大学法人鳥取大学 | メチル化関連酵素ｈａｔ１とｋａｔ８の阻害薬 |
| JP7534070B2 (ja) | 2015-11-04 | 2024-08-14 | フェイト セラピューティクス，インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
| CN115806940A (zh) | 2015-11-04 | 2023-03-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| BR112018016450A2 (pt) | 2016-02-12 | 2018-12-26 | Bluebird Bio Inc | composições intensificadoras de vcn e métodos de uso das mesmas |
| WO2017139561A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| CA3014667A1 (en) * | 2016-03-04 | 2017-09-08 | The Board Of Trustees Of Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin e2 |
| US9918994B2 (en) | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| US11229662B2 (en) | 2016-11-15 | 2022-01-25 | The Schepens Eye Research Institute, Inc. | Compositions and methods for the treatment of aberrant angiogenesis |
| TWI719315B (zh) * | 2017-06-07 | 2021-02-21 | 中央研究院 | 移除未分化的萬能性幹細胞之方法 |
| CN111212648B (zh) | 2017-06-09 | 2024-07-09 | 莱兰斯坦福初级大学评议会 | 用于预防或治疗肌肉疾患的组合物和方法 |
| EP3672590B1 (en) * | 2017-08-22 | 2025-02-12 | The Children's Medical Center Corporation | Methods for inducing hematopoietic stem cell specificity |
| US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| JP7416700B2 (ja) | 2017-11-14 | 2024-01-17 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | 増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法 |
| EP3597211A1 (en) | 2018-07-19 | 2020-01-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Periostin compounds for the treatment of haematological complications |
| CN109609455A (zh) * | 2018-12-28 | 2019-04-12 | 诺未科技（北京）有限公司 | 扩增造血干细胞的培养体系、方法及其用途 |
| US20220127576A1 (en) * | 2019-02-13 | 2022-04-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for stem cell therapy |
| CN110051839A (zh) * | 2019-04-16 | 2019-07-26 | 诺航生物技术(徐州)有限公司 | 一种促进脐带血干细胞体外扩增和增强脐带血干细胞移植后造血重建功能的药物 |
| FI130749B1 (en) * | 2020-01-24 | 2024-02-26 | Faron Pharmaceuticals Oy | USE OF VAP-1 INHIBITOR IN THE EX VIVO CULTURE OF HEMATOPOEITIC STEM CELLS AND IN THE TREATMENT OF BONE Marrow Loss or BONE Marrow Dysfunction |
| EP4146797A1 (en) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| US11883436B2 (en) | 2020-08-17 | 2024-01-30 | The Board Of Trustees Of The University Of Illinois | Method of preparing hematopoietic stem and progenitor cells for transplantation |
| AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
| GB202206346D0 (en) | 2022-04-29 | 2022-06-15 | Ospedale San Raffaele Srl | Gene therapy |
| KR20240136869A (ko) | 2023-03-07 | 2024-09-19 | 인제대학교 산학협력단 | 조혈 줄기세포 증식 또는 가동화 촉진용 조성물 및 가동화 조혈 줄기세포 수집방법 |
| US20250332260A1 (en) | 2024-04-10 | 2025-10-30 | Garuda Therapeutics, Inc. | Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA103846A (en) | 1906-12-03 | 1907-02-26 | William Bell | Manufacture of half-tone printing blocks |
| US3217903A (en) | 1961-01-19 | 1965-11-16 | Mc Graw Edison Co | Segregating control |
| US3753357A (en) | 1970-12-14 | 1973-08-21 | Ovitron Res Corp | Method and apparatus for the preservation of cells and tissues |
| US4199022A (en) | 1978-12-08 | 1980-04-22 | The United States Of America As Represented By The Department Of Energy | Method of freezing living cells and tissues with improved subsequent survival |
| US4239679A (en) | 1979-06-27 | 1980-12-16 | Diamond Shamrock Corporation | High bulk density rigid poly(vinyl chloride) resin powder composition and preparation thereof |
| HU181154B (en) | 1980-07-18 | 1983-06-28 | Epitestudomanyi Intezet | Shaped building unit and space limiting or dividing structure made of same as well as method for producing the shaped building unit |
| US4559298A (en) | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
| US5004681B1 (en) | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
| SG59931A1 (en) * | 1989-10-16 | 1999-02-22 | Amgen Inc | Stem cell factor |
| US5114672A (en) | 1990-08-27 | 1992-05-19 | Cryo-Cell International, Inc. | Method for preserving blood fluid |
| AU702871B2 (en) * | 1993-08-23 | 1999-03-11 | Nexell Therapeutics Inc. | (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media |
| AU6125396A (en) * | 1995-06-07 | 1996-12-30 | Novartis Ag | Serum-free media for primitive hematopoietic cells and metho ds of use thereof |
| US6372796B1 (en) | 1996-11-13 | 2002-04-16 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
| GB9904281D0 (en) * | 1999-02-24 | 1999-04-21 | Reneuron Ltd | Transplantation |
| RU2259830C2 (ru) | 1999-11-24 | 2005-09-10 | Оно Фармасьютикал Ко., Лтд. | Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы |
| TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| US6226997B1 (en) | 1999-12-07 | 2001-05-08 | Cryo-Cell International, Inc. | Method and device for maintaining temperature integrity of cryogenically preserved biological samples |
| US6852534B2 (en) | 2000-11-03 | 2005-02-08 | Kourion Therapeutics Gmbh | Method to determine an engrafting cell dose of hematopoietic stem cell transplant units |
| JP4077158B2 (ja) | 2001-01-10 | 2008-04-16 | 株式会社メニコン | 植物性繊維分解剤およびそれを用いた植物性廃棄物の処理法 |
| MXPA03007175A (es) | 2001-02-14 | 2005-02-14 | Anthrogenesis Corp | Placenta de mamiferos postparto, su uso y celulas madres placentales extraidas de ella. |
| FR2825261B1 (fr) | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | Ligne de prelevement du sang placentaire comprenant une poche de rincage |
| US7179643B2 (en) | 2001-06-14 | 2007-02-20 | Reliance Life Sciences Pvt. Ltd. | Device and a process for expansion of haemopoeitic stem cells for therapeutic use |
| WO2003042405A2 (en) | 2001-11-15 | 2003-05-22 | Children's Medical Center Corporation | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof |
| WO2003055989A2 (en) * | 2001-12-21 | 2003-07-10 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
| RU2205627C1 (ru) * | 2002-05-30 | 2003-06-10 | Открытое акционерное общество "Косметическое объединение "Свобода" | Крем для лица, выводящий токсины |
| JP4497320B2 (ja) | 2002-10-10 | 2010-07-07 | 小野薬品工業株式会社 | 内因性修復因子産生促進剤 |
| WO2004078169A1 (en) | 2003-03-04 | 2004-09-16 | Pfizer Products Inc. | Use of ep2 selective receptor agonists in medical treatment |
| US20050054103A1 (en) * | 2003-03-07 | 2005-03-10 | Tony Peled | Expansion of renewable stem cell populations using modulators of PI 3-kinase |
| EP1613742A2 (en) | 2003-04-08 | 2006-01-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same |
| GB0324523D0 (en) | 2003-10-21 | 2003-11-26 | Medical Res Council | Compositions and methods of treatment |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
| WO2006005153A1 (en) * | 2004-07-09 | 2006-01-19 | Bc Cancer Agency | Nup98-hox fusions for expansion of hemopoietic stem cells |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| WO2006078886A2 (en) | 2005-01-18 | 2006-07-27 | Irm Llc | Compounds and compositions as wnt signaling pathway modulators |
| CA2597757C (en) | 2005-02-10 | 2016-06-28 | Regents Of The University Of Minnesota | Vascular/lymphatic endothelial cells |
| WO2007117262A2 (en) | 2005-07-29 | 2007-10-18 | Athersys, Inc. | Culture of non-embryonic cells at high cell density |
| JP4562618B2 (ja) | 2005-08-18 | 2010-10-13 | 陽一 佐藤 | 空き缶処理車 |
| US8318489B2 (en) * | 2005-12-22 | 2012-11-27 | Bruce Paul Davidson | Prostacyclin directed differentiation of cardiomyocytes from human embryonic stem cells |
| MX373998B (es) | 2006-03-24 | 2020-07-22 | Childrens Medical Center | Uso de un modulador de células madre hematopoyeticas (hsc) para promover el crecimiento de hsc. |
| US8241903B2 (en) | 2006-06-22 | 2012-08-14 | Yeda Research And Development Co., Ltd. | Catecholamine receptor modulation |
| WO2008021475A2 (en) | 2006-08-16 | 2008-02-21 | The General Hospital Corporation | Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis |
| KR20080042761A (ko) | 2006-11-10 | 2008-05-15 | 문찬일 | 렙틴을 이용한 줄기세포 증식방법 |
| WO2008073748A1 (en) * | 2006-12-08 | 2008-06-19 | University Of Rochester | Expansion of hematopoietic stem cells |
-
2007
- 2007-03-26 MX MX2015007504A patent/MX373998B/es unknown
- 2007-03-26 RU RU2008142106A patent/RU2425876C2/ru active
- 2007-03-26 AU AU2007230902A patent/AU2007230902B2/en not_active Ceased
- 2007-03-26 EP EP20110004943 patent/EP2423303A1/en not_active Withdrawn
- 2007-03-26 CN CN201210050521.9A patent/CN102626517B/zh active Active
- 2007-03-26 EP EP07773772A patent/EP1999255A2/en not_active Withdrawn
- 2007-03-26 ZA ZA200808123A patent/ZA200808123B/xx unknown
- 2007-03-26 MX MX2008012178A patent/MX2008012178A/es active IP Right Grant
- 2007-03-26 CN CN200780018870XA patent/CN101495623B/zh active Active
- 2007-03-26 RU RU2011115827/10A patent/RU2493252C2/ru active
- 2007-03-26 WO PCT/US2007/007419 patent/WO2007112084A2/en not_active Ceased
- 2007-03-26 EP EP18175819.4A patent/EP3424507A1/en not_active Withdrawn
- 2007-03-26 CA CA2647201A patent/CA2647201C/en active Active
- 2007-03-26 JP JP2009501606A patent/JP5247675B2/ja active Active
- 2007-04-26 US US12/294,344 patent/US8168428B2/en not_active Expired - Fee Related
-
2008
- 2008-09-23 MX MX2019007494A patent/MX2019007494A/es unknown
-
2009
- 2009-09-21 ZA ZA200906574A patent/ZA200906574B/xx unknown
-
2012
- 2012-03-27 US US13/431,534 patent/US8551782B2/en not_active Expired - Fee Related
- 2012-03-27 US US13/431,563 patent/US9028811B2/en active Active
- 2012-03-27 US US13/431,499 patent/US8563310B2/en not_active Expired - Fee Related
-
2013
- 2013-03-08 JP JP2013046473A patent/JP6041711B2/ja not_active Expired - Fee Related
- 2013-03-15 US US13/837,265 patent/US20130209424A1/en not_active Abandoned
- 2013-03-15 US US13/836,794 patent/US10278990B2/en active Active
- 2013-03-15 US US13/838,002 patent/US10272110B2/en active Active
-
2015
- 2015-07-27 JP JP2015147317A patent/JP6208719B2/ja active Active
-
2016
- 2016-09-08 JP JP2016175313A patent/JP6530732B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-19 JP JP2019027038A patent/JP6797222B2/ja not_active Expired - Fee Related
- 2019-09-20 JP JP2019171346A patent/JP2019214620A/ja not_active Withdrawn
-
2021
- 2021-10-19 JP JP2021170835A patent/JP2022025091A/ja active Pending
-
2023
- 2023-06-16 JP JP2023098876A patent/JP2023112027A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009530408A5 (enExample) | ||
| RU2008142106A (ru) | Способ модулирования роста гематопоэтических стволовых клеток | |
| JP2012040394A5 (enExample) | ||
| WO2010087986A3 (en) | Resuscitation fluid | |
| WO2009099539A3 (en) | (meth)acrylate surfaces for cell culture, methods of making and using the surfaces | |
| WO2013176106A1 (ja) | 細胞シート搬送用容器 | |
| EA200900462A1 (ru) | Контейнер для хранения косметических изделий (варианты) и способ извлечения емкости из контейнера | |
| ATE543537T1 (de) | Wimperntuschezusammensetzung mit ethylen-vinyl- acetat-copolymer | |
| BR112012028045A2 (pt) | unidade de distribuição, e, método para distribuir um líquido sob pressão | |
| WO2010108028A3 (en) | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same | |
| NZ607458A (en) | Ovenable heat-sealed package | |
| JP2023101552A (ja) | 挟持具 | |
| EP2194020A3 (de) | Befüllvorrichtung | |
| Capobianco et al. | Effects of natural ligands of PPARγ on lipid metabolism in placental tissues from healthy and diabetic rats | |
| CN201322489Y (zh) | 双密封精液冻存管 | |
| AR082316A1 (es) | Complejo inmunomagnetico y su uso en la determinacion de grupo/fenotipificacion de celulas rojas de la sangre | |
| MX357515B (es) | Aparato y métodos para secuestrar fluidos expulsados durante la transferencia de fluido. | |
| MX2012006540A (es) | Dispositivo de abertura y metodo de manufactura del mismo, y recipiente de envasado proporcionado con el dispositivo de abertura. | |
| RU2013145425A (ru) | Культуральная среда для мезенхимальных стволовых клеток человека | |
| CL2009000768A1 (es) | Metodo para identificar polipeptidos que comprenden un determinante antigenico de reaccion cruzada que comprende las etapas de obtener un anticuerpo de un animal expuesto secuencialmente a dos desafios con dos polipeptidos con determinantes antigenicos de una misma especie, pero distinto serotipo. | |
| CN102845414B (zh) | 冻存管结构 | |
| Jiang et al. | Cyclooxygenase expression is elevated in retinoic acid-differentiated U937 cells | |
| IL318944A (en) | Methods and components for stimulating pancreatic beta cells based on small molecules | |
| CN201469882U (zh) | 一种手持式给药器 | |
| FR3136996A1 (fr) | Dispositif et procédé d’injection d’un gaz dans une canalisation de transport d’un fluide |